The Hematologist

banner image

Beyond Business As Usual

Dr. Anderson outlines six major ASH strategic initiatives and goals for the coming years discussed at the 2017 Executive Committee Spring Retreat in Canada.

Read more
banner image

Clinical Trials Corner

Dr. Roberts looks at a study that compares chemoimmunotherapy with three combinations of non-DNA damaging drugs as first-line therapy for fit patients.

Read more
banner image

Policy Podcast

Drs. Rosmarin and Alvarnas update ASH members on key policy topics affecting hematologists, including research funding, drug access and pricing issues, and efforts to repeal the ACA.

Play here
Current Issue Static Feature

Current Issue

July/August 2017              
Volume 14, Issue 4

Read current issue

President's Column

Presidents Column - Kenneth AndersonKraft Family Professor of Medicine, Harvard Medical School; Director Lebow Institute for Myeloma Therapeutics and Jerome Lipper Myeloma Center Dana-Farber Cancer Institute, Boston, MA
Beyond Business As Usual
July 1, 2017

Dr. Kenneth Anderson outlines six major ASH strategic initiatives and goals for the coming years discussed at the 2017 Execxutive Committee Spring Retreat in Canada.

View all president's column articles

  • DEA Eliminates Grace Period for Registration Renewal
    December 21, 2016

    Through a notice on its website, the Drug Enforcement Administration (DEA) recently announced significant changes to its registration renewal process. Effective January 1, 2017, the DEA is eliminating the informal grace period which the agency has previously allowed for registrants to renew their registrations. 

  • CMS Announces End to Medicare Part B Drug Payment Model
    December 20, 2016

    On December 15, 2016, the Centers for Medicare and Medicaid Services (CMS) announced the cancellation of Medicare Part B Drug Payment Model.  CMS initially proposed the demonstration on March 8, 2016 to test new models in how physician-administered drugs are paid under the Medicare program.

  • NHLBI Small Business Innovation Research Funding Opportunity Fosters Production of Blood Cells From Stem Cells
    November 23, 2016

    ASH is pleased to see the National Heart, Lung and Blood Institute’s (NHLBI) continuous support (RFA-HL-15-030) for the development of improved techniques to enhance the production of clinically relevant, functional stem cell-derived red blood cells or platelets.

  • 2016 ASH Advocacy Efforts Related to Sickle Cell Disease and Sickle Cell Trait
    November 17, 2016

    The American Society of Hematology (ASH) is committed to addressing the burden of sickle cell disease (SCD) and is undertaking a multifaceted initiative to improve outcomes for individuals with the disease, both in the United States and globally.

View all Policy News